Director of Discovery Technology at Cancer Therapeutics CRC male cancer researcher

Dr Hendrik Falk

Director, Discovery Technology

Director of Discovery Technology at Cancer Therapeutics CRC male cancer researcher

Dr Hendrik Falk was awarded a B.A. in Business Information Technology and then studied pharmacy at the Martin-Luther Universität Halle/ Germany, receiving the licence to practise in 2000. During his doctoral thesis at the Freie Universität Berlin, Dr Falk examined the involvement of G proteins in cellular signalling. During post-doctoral studies in the Molecular Tumour Genetics group at the Max-Delbrück-Center, Berlin/ Germany, Dr Falk expanded his skills to the high-throughput screening for ligands of G protein coupled receptors. Hendrik brings extensive knowledge in molecular biology as well as biochemical and cellular assays of mammalian cells to the HTCS.

Dr Falk joined the HTCS group as a Research Officer in 2008. He is responsible for designing, developing and implementing high throughput screens and follow-up studies in collaboration with the sponsoring research group. His responsibilities predominantly include providing assay/database support for the Co-operative Research Centre for Cancer Therapeutics projects.